AbbVie is stumping up more than $188 per share for Ireland-domiciled Allergan, best known for wrinkle treatment Botox, which is a 45% premium to its closing price before the deal was announced.

Evolus' flagship product is Jeuveau, a neurotoxin filler like AbbVie's Botox. Botox is easily the market leader — its name synonymous with smoothing wrinkles. As a cosmetic drug, Botox is ...

Skyrizi and Rinvoq use in gastroenterology grew over 40% year-over-year. Cantor gave AbbVie an Overweight rating with a $210 price target. Markets are messy—but the right setups can still ...

A report by the Senate Finance Committee has concluded that AbbVie exploited a financial loophole introduced by former President Donald Trump in 2017 to avoid paying "billions in taxes." The ...

AbbVie (NYSE:ABBV) is scheduled to announce its earnings on Friday, April 25, 2025. Currently, the company holds a market capitalization of $307 billion. Over the past twelve months, AbbVie ...

Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options ... new products and drugs in aesthetics (including Botox). With a trading volume of 6,292,250, the price ...

AbbVie’s neuroscience efforts are paying off and seeing robust growth (up 16.6% year-over-year) thanks particularly to Botox Therapeutic (migraines, overactive bladder, spasticity) and Vraylar ...

Botox now has competitors making chemically similar products – rival drugs include Dysport, produced by France’s Ipsen and Xeomin from Germany’s Merz. But AbbVie says it is confident it can ...

It's been a stomach-churning past few months for investors in pharmaceutical giant AbbVie (NYSE: ABBV). A potential blockbuster drug that AbbVie spent roughly $9 billion to acquire the rights to ...